Lilly USA, LLC Launches New Rotation Programme for Medical Students
Lilly USA, LLC has launched a new rotation programme for aspiring physicians. The rotation assignments cut across different aspects of the pharmaceutical company's business — from drug discovery and development to bioethics and patient safety — providing third- and fourth-year medical students a lens into the pharmaceutical industry, its vision and focus on improving patient outcomes.
Students from Tulane University School of Medicine will be the first to participate in the pilot programme at Eli Lilly and Company's Indianapolis headquarters.
"We're excited to kick off the Medical Student Rotation Programme," said Yolanda Johnson-Moton, director of external relations, US Medical Division, Lilly. "The students selected for this program distinguished themselves, both academically and during the interview process.
"The programme is intensive and exposes these future practitioners to the various scientific and medical phases of the drug development process, along with a holistic view of the company. Students have a unique vantage point and opportunity to work alongside some of the most talented health care professionals in the industry, including physicians, and understand their important roles in our organisation."
The Medical Student Rotation Programme is a 4-week experiential learning programme. In partnership with Tulane University School of Medicine, medical students will gain experience and understanding of drug development and how physicians at Lilly contribute to the process. The programme features a student-centric curriculum and structured mentorship in various aspects of pharmaceutical development. This includes independent projects, industry-led workshops, exposure to many facets of drug discovery and development and networking opportunities with Lilly medical leaders.
"Students participating in the programme will get hands-on knowledge of the many roles physicians play in the pharmaceutical industry," said Dr Marc J. Kahn, senior associate dean for admissions and student affairs at Tulane University School of Medicine. "The partnership between Lilly and Tulane matches Lilly's commitment to medical education with Tulane's passion for providing exciting educational experiences for our students. Tulane has the largest combined MD/MPH programme in the country, a successful MD/MBA programme and a programme in medical innovation. This experience combined with Lilly's reputation as a leader in the pharmaceutical industry makes the partnership a natural one."
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance